NTRK1 Fusion

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Carcinoma1
TPM3::NTRK1 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID11692 The goal of this study was to assess the efficacy and safety of larotrectinib in patients with TRK fusion–positive lung cancers. This was achieved by reviewing data from two global, multicenter clinic… (full text at CIViC) PMID 35085007 · Drilon et al., 2022 · Open in CIViC	civic
Malignant Colorectal Neoplasm1
TPM3::NTRK1 Fusion	Larotrectinib + LestaurtinibSubstitutes	Predictive	D	Supports Sensitivity Response	2	accepted	EID978 NTRK1 fusions (one LMNA-NTRK1 and two TPM3-NTRK1) were identified in 2% of Korean colorectal cancer patients (147 patients). TrkA (NTRK1) protein expression was associated with presence of NTRK1 gene …

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Lung Carcinoma1

TPM3::NTRK1 Fusion

Larotrectinib

Predictive

Supports Sensitivity Response

accepted

EID11692

The goal of this study was to assess the efficacy and safety of larotrectinib in patients with TRK fusion–positive lung cancers. This was achieved by reviewing data from two global, multicenter clinic… (full text at CIViC)

PMID 35085007 · Drilon et al., 2022 · Open in CIViC

civic

Malignant Colorectal Neoplasm1

TPM3::NTRK1 Fusion

Larotrectinib + LestaurtinibSubstitutes

Predictive

Supports Sensitivity Response

accepted

EID978

NTRK1 fusions (one LMNA-NTRK1 and two TPM3-NTRK1) were identified in 2% of Korean colorectal cancer patients (147 patients). TrkA (NTRK1) protein expression was associated with presence of NTRK1 gene …

Malignant Neoplasm1
TPM3::NTRK1 Fusion	Entrectinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID10094 BaF3 cells transduced with a number of NTRK fusions demonstrated sensitivity to entrectinib. IC50 values were measured from cell viability assays (Cell Titer Glo) following 72-hour incubation with ent… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic

Malignant Neoplasm1

TPM3::NTRK1 Fusion

Entrectinib

Predictive

Supports Sensitivity Response

accepted

EID10094

BaF3 cells transduced with a number of NTRK fusions demonstrated sensitivity to entrectinib. IC50 values were measured from cell viability assays (Cell Titer Glo) following 72-hour incubation with ent… (full text at CIViC)

PMID 26884591 · Drilon et al., 2016 · Open in CIViC

civic

Malignant Ovarian Neoplasm1
TPM3::NTRK1 Fusion	Entrectinib	Predictive	C	Does Not Support Resistance	2	submitted	EID11743 56-year-old women was diagnosed with a stage IV ovarian cancer. Debulking surgery, and chemotherapy was given for 10 months. However, disease recurred and at this time NGS was performed which detected… (full text at CIViC) PMID 35251641 · Endo et al., 2022 · Open in CIViC	civic

Malignant Ovarian Neoplasm1

TPM3::NTRK1 Fusion

Entrectinib

Predictive

Does Not Support Resistance

submitted

EID11743

56-year-old women was diagnosed with a stage IV ovarian cancer. Debulking surgery, and chemotherapy was given for 10 months. However, disease recurred and at this time NGS was performed which detected… (full text at CIViC)

PMID 35251641 · Endo et al., 2022 · Open in CIViC

civic

Myofibroma1
TPM3::NTRK1 Fusion	Entrectinib	Predictive	C	Supports Sensitivity Response	1	accepted	EID11861 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with infantile… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic

Myofibroma1

TPM3::NTRK1 Fusion

Entrectinib

Predictive

Supports Sensitivity Response

accepted

EID11861

In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with infantile… (full text at CIViC)

PMID 35395680 · Desai et al., 2022 · Open in CIViC

civic

Sarcoma1
TPM3::NTRK1 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	4	accepted	EID6101 Four patients with infantile fibrosarcoma and soft tissue sarcoma and a TPM3::NTRK1 fusion were treated with larotrectinib. All four patients had a partial or complete response in the target lesion. T… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC	civic

Sarcoma1

TPM3::NTRK1 Fusion

Larotrectinib

Predictive

Supports Sensitivity Response

accepted

EID6101

Four patients with infantile fibrosarcoma and soft tissue sarcoma and a TPM3::NTRK1 fusion were treated with larotrectinib. All four patients had a partial or complete response in the target lesion. T… (full text at CIViC)

PMID 29606586 · Laetsch et al., 2018 · Open in CIViC

civic

Solid Neoplasm1
TPM3::NTRK1 Fusion	Larotrectinib Regimen	Predictive	A	Supports Sensitivity Response	5	accepted	EID11703 This was a Phase 1/2 study in which 55 patients between 4 months and 76 years of age with TRK-fusion positive tumors were given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion type… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC	civic

Solid Neoplasm1

TPM3::NTRK1 Fusion

Larotrectinib Regimen

Predictive

Supports Sensitivity Response

accepted

EID11703

This was a Phase 1/2 study in which 55 patients between 4 months and 76 years of age with TRK-fusion positive tumors were given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion type… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

civic

Spindle Cell Sarcoma1
TPM3::NTRK1 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID7419 In a pediatric phase 1 trial (NCT02637687), a 12-year-old boy with TPM3-NTRK1 fusion was treated with Larotrectinib as first line treatment as no standard treatment options were available. Following a… (full text at CIViC) PMID 30204247 · DuBois et al., 2018 · Open in CIViC	civic

Spindle Cell Sarcoma1

TPM3::NTRK1 Fusion

Larotrectinib

Predictive

Supports Sensitivity Response

accepted

EID7419

In a pediatric phase 1 trial (NCT02637687), a 12-year-old boy with TPM3-NTRK1 fusion was treated with Larotrectinib as first line treatment as no standard treatment options were available. Following a… (full text at CIViC)

PMID 30204247 · DuBois et al., 2018 · Open in CIViC

civic

Thyroid Gland Papillary Carcinoma1
TPM3::NTRK1 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID8042 A healthy 12 year old with right neck mass was found to have heterogeneous solid mass originating from the right thyroid lobe. Total thyroidectomy confirmed papillary thyroid carcinoma (PTC) with mult… (full text at CIViC) PMID 29610391 · Ronsley et al., 2018 · Open in CIViC	civic

Thyroid Gland Papillary Carcinoma1

TPM3::NTRK1 Fusion

Larotrectinib

Predictive

Supports Sensitivity Response

accepted

EID8042

A healthy 12 year old with right neck mass was found to have heterogeneous solid mass originating from the right thyroid lobe. Total thyroidectomy confirmed papillary thyroid carcinoma (PTC) with mult… (full text at CIViC)

PMID 29610391 · Ronsley et al., 2018 · Open in CIViC

civic

Evidence by cancer (9 items)

Clinical significance (0)